Pharmaceutical company AstraZeneca has signed a deal worth nearly $247 million with Absci, an artificial intelligence company, to develop antibodies to fight cancer, Reuters reports.
Absci’s collaboration with AstraZeneca is aimed at creating a generative AI model with a minimum level of risk for the development of new advanced antibodies. So far, the companies have not announced which type of cancer they are focusing their efforts on.
Absci uses AI to develop medicines based on how well they work with specific targets in the body, how safe they are, and other factors.
“We are excited to be working with AstraZeneca to use our AI to develop new treatments for cancer patients.”
Absci CEO Sean McClain